Center for Stem Cell Therapeutics and Imaging (CSTI), Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Sci Rep. 2020 Feb 4;10(1):1779. doi: 10.1038/s41598-020-58072-w.
Dysregulation of miRNA expression has been implicated in cancer. Numerous strategies have been explored to modulate miR but sub-optimal delivery and inability to concurrently target multiple pathways involved in tumor progression have limited their efficacy. In this study, we explored the potential co-modulation of upregulated miR-21 and downregulated miR-7 to enhance therapeutic outcomes in heterogenic tumor types. We first engineered lentiviral (LV) and adeno-associated viral (AAV) vectors that preferentially express anti-sense miR against miR-21(miRzip-21) and show that modulating miR-21 via miRzip extensively targets tumor cell proliferation, migration and invasion in vitro in a broad spectrum of cancer types and has therapeutic efficacy in vivo. Next, we show a significantly increased expression of caspase-mediated apoptosis by simultaneously downregulating miR-21 and upregulating miR-7 in different tumor cells. In vivo co-treatment with AAV-miRzip-21 and AAV-miR-7 in mice bearing malignant brain tumors resulted in significantly decreased tumor burden with a corresponding increase in survival. To our knowledge, this is the first study that demonstrates the therapeutic efficacy of simultaneously upregulating miR-7 and downregulating miR-21 and establishes a roadmap towards clinical translation of modulating miRs for various cancer types.
miRNA 表达失调与癌症有关。人们已经探索了许多调节 miRNA 的策略,但由于递药效果不理想,并且无法同时针对肿瘤进展中涉及的多个途径进行靶向治疗,因此其疗效受到限制。在这项研究中,我们探讨了上调的 miR-21 和下调的 miR-7 同时调控以增强异质肿瘤类型治疗效果的潜力。我们首先设计了优先表达针对 miR-21 的反义 miRNA 的慢病毒 (LV) 和腺相关病毒 (AAV) 载体(miRzip-21),并证明通过 miRzip 调节 miR-21 可广泛靶向体外多种癌症类型的肿瘤细胞增殖、迁移和侵袭,并具有体内治疗效果。接下来,我们表明在不同的肿瘤细胞中同时下调 miR-21 和上调 miR-7 可显著增加 caspase 介导的细胞凋亡。在患有恶性脑肿瘤的小鼠中,AAV-miRzip-21 和 AAV-miR-7 的联合治疗可显著降低肿瘤负担,同时提高存活率。据我们所知,这是第一项证明同时上调 miR-7 和下调 miR-21 的治疗效果的研究,并为针对各种癌症类型的 miR 调节的临床转化建立了路线图。